TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12426517
Drug: Nasal methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal methadone (10 mg)
Study: 12426517
Drug: Intravenous methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methadone (10 mg)
Study: 12426517
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (10 mg)
Study: 8765442
Drug: High-dose ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ondansetron
Study: 8765442
Drug: Single-dose ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ondansetron
Study: 1834161
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg loading dose; A: 4 mg i.v. + 4 mg orally; B: 8 mg i.v.), followed by oral treatment for 5 days (A: 6‐hourly; B: 8 mg 8‐hourly)
Study: 6349653
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (200 mg/day for 1 week, 250 mg/day for 2nd week, 300 mg/day for 3rd to 8th week)
Study: 6349653
Drug: Indometacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (100 mg/day for 1 week, 125 mg/day for 2nd week, 150 mg/day for 3rd to 8th week)
Study: 30158029
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine injection (20 ml) at port sites
Study: 30158029
Drug: No bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bupivacaine injection
Study: 26871297
Drug: Extended-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release guanfacine hydrochloride (GXR)
Study: 22830389
Drug: MTX 25
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 25 mg once weekly
Study: 22830389
Drug: MTX 10
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 10 mg once weekly
Study: 20832994
Drug: Nicorandil (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (bolus injection of 100 μg/kg, continuous injection of 60‐100 μg/kg/h for 5 days)
Study: 17369799
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g day(‐1) of creatine monohydrate for 21 days)
Study: 16379507
Drug: risperidone (0.5-3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (0.5-3.5 mg/day)
Study: 10051720
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with HDM extract (Alavac, Bencard) for 2 years
Study: 28482901
Drug: Daily listening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily listening to specially composed songs for 12 weeks
Study: 28482901
Drug: Daily relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily relaxation for 12 weeks
Study: 23023407
Drug: 0.1% pranoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% pranoprofen (PN) eye drops, 4 times daily for 4 weeks
Study: 23023407
Drug: 0.1% fluorometholone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluorometholone (FL) eye drops, 4 times daily for 4 weeks
Study: 21613025
Drug: Dentin desensitizer
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dentin desensitizer and ozone treatment
Study: 19111473
Drug: Weekly infusional
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly infusional 5‐FU 2250 mg/m2 over 48 h plus bimonthly oxaliplatin 85 mg/m2
Study: 19111473
Drug: Weekly infusional
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly infusional 5‐FU plus oxaliplatin
Study: 16710073
Drug: Low-dose pioglitazone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pioglitazone (7.5 mg/day)
Study: 16710073
Drug: Standard-dose pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose pioglitazone (15 mg/day)
Study: 3315397
Drug: 1% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% amino acid dialysis solution
Study: 269880
Drug: Pluronic F‐127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pluronic F‐127 plus sodium citrate gel
Study: 269880
Drug: Pluronic F‐127
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pluronic F‐127 gel
Study: 21207920
Drug: 0.4% stannous
Normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% stannous fluoride gel
Study: 26028283
Drug: Fasting/exercise/saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting/exercise/saline infusion
Study: 26028283
Drug: Fasting/rest/iv glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting/rest/iv glucose infusions
Study: 19156856
Drug: No history
Approvals — FDA: no, EMA: no, PMDA: no
Description: No history of chemotherapy
Study: 19156856
Drug: Future radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Future radiation therapy planned post study recruitment
Study: 15119910
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT), administered 3 times weekly
Study: 27302143
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate plus sodium hyaluronate (9 mg)
Study: 27302143
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate plus saline solution
Study: 29466159
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg daily)
Study: 19036898
Drug: NOS inhibition
Normalized name: C1-inhibiting factor
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOS inhibition (10 mM N(G)-nitro-l-arginine methyl ester)
Study: 10912743
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no aspirin)
Study: 17382603
Drug: Rifaximin 200
Normalized name: rifAXIMin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 200 mg 3 times daily for 3 days
Study: 17382603
Drug: Rifaximin-loperamide combination
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin-loperamide combination therapy
Study: 17382603
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg initially followed by 2 mg after each unformed stool)
Study: 14711550
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone therapy (50 microg/d of E(2) and 140-170 microg/d of norethisterone acetate; n = 12)
Study: 14711550
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (2 mg of E(2) and 1 mg of norethisterone acetate; n = 12)
Study: 11290880
Drug: Donepezil (DPZ)
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil (DPZ) 5-10 mg/d
Study: 11290880
Drug: Rivastigmine (Riv)
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine (Riv) 1.5 to 12 mg/d
Study: 8049645
Drug: Cytotoxic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic therapy
Study: 2465391
Drug: PVP16B (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP16B (cisplatin plus etoposide plus bleomycin) administered in three courses over 9 weeks
Study: 2465391
Drug: PVP16B (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVP16B (cisplatin plus etoposide plus bleomycin) administered in four courses over 12 weeks
Study: 15554757
Drug: Topiramate (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (titrated from 25 mg/day to a maximum of 600 mg/day)
Study: 11912568
Drug: Topiramate (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (not specified dosage)
Study: 9778280
Drug: Glycopyrrolate 2
Normalized name: glycopyrrolate 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 2 mg twice daily
Study: 7523607
Drug: Localized disease
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Localized disease treatment (MOPP plus radiation)
Study: 3220232
Drug: Acetorphan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetorphan (2.5 mg/kg intravenously at a constant rate in 20 min)
Study: 30548111
Drug: Activity-oriented therapy
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity-oriented therapy (cooking)
Study: 29706047
Drug: Qilin Pills
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qilin Pills (6 g tid for 12 weeks)
Study: 29706047
Drug: Wuziyanzong Pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuziyanzong Pills (6 g bid for 12 weeks)
Study: 23400750
Drug: Intravaginal taggant
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal taggant (2‐butyl acetate, 2‐pentyl acetate, isopropyl butyrate, or 2‐pentyl butyrate; 30 mg) in hydroxyethylcellulose or tenofovir placebo gel
Study: 23400750
Drug: Dermal administration
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal administration of the same formulations
Study: 20512389
Drug: Test tablets
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablets containing bovine lactoferrin and lactoperoxidase
Study: 19250310
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of BoNT‐A (20 U and 30 U)
Study: 17295590
Drug: diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 0.1 mg/kg
Study: 8442971
Drug: diazepam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 0.3 mg/kg
Study: 9621667
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg.kg‐1) with lidocaine (group ML)
Study: 9621667
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg.kg‐1) (group L)
Study: 30792007
Drug: BUP‐XR 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP‐XR 300 mg/300 mg
Study: 30792007
Drug: BUP‐XR 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP‐XR 300 mg/100 mg
Study: 30107404
Drug: Fronto-temporal transcranial
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fronto-temporal transcranial direct current stimulation (tDCS) with 2-mA, twice-daily sessions for 5 consecutive days.
Study: 26735919
Drug: 2-hour reduction
Normalized name: REDUCTIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour reduction in daily sitting
Study: 22551119
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of 150 ml tomato juice (15 mg lycopene) for 5 weeks
Study: 10465129
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g three times daily
Study: 10465129
Drug: Cefepime 2
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2 g twice daily
Study: 157076
Drug: Metronidazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (200 mg or 400 mg three times daily for 10 days)
Study: 25787200
Drug: fasiglifam 50
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasiglifam 50 mg
Study: 25787200
Drug: fasiglifam 25
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasiglifam 25 mg
Study: 18824040
Drug: Cortisol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (30 mg oral dose)
Study: 15538933
Drug: GHRH antagonist
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH antagonist (N‐Ac‐Tyr(1), D‐Arg(2)) GHRH‐29 (NH(2))
Study: 11288008
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (18 patients)
Study: 9040547
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of zinc per day for the first 3 days of TPN
Study: 9040547
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of zinc per day for the first 3 days of TPN
Study: 30115054
Drug: Daily Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Physical Activity (DPA) program consisting of 20 minutes of teacher-led DPA for 20 consecutive weeks
Study: 26280577
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA)
Study: 25742320
Drug: Mobile phone
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile phone intervention (customised, interactive, automated voice reminders sent weekly)
Study: 22943559
Drug: Rectal TFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal TFV 1% gel (7-day exposure)
Study: 22943559
Drug: Rectal TFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal TFV 1% gel (single exposure)
Study: 22943559
Drug: Rectal TFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal TFV 1% gel (single and 7-day exposure)
Study: 22943559
Drug: Oral TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TDF (300 mg single exposure)
Study: 22943559
Drug: Hydroxyethyl cellulose
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl cellulose (HEC) placebo gel
Study: 11958408
Drug: Bioactive glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioactive glass grafting material used in dental implants
Study: 10418907
Drug: DTwP//PRP‐T vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP//PRP‐T vaccine (group A, N = 85)
Study: 10418907
Drug: DTwP//Placebo vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwP//Placebo vaccine (group B, N = 83)
Study: 10418907
Drug: DT booster
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DT booster dose at age 5 years (subgroup B1)
Study: 10418907
Drug: Hib polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib polysaccharide (PRP) vaccine (subgroups A2 and B2)
Study: 1705089
Drug: Thrombin infusion
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin infusion via a four-way balloon catheter (5,000 U in 5 ml of saline)
Study: 1705089
Drug: Thrombin infusion
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin infusion group
Study: 26687697
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil (2400 mg/d; DHA: 1450 mg, EPA: 400 mg)
Study: 12867218
Drug: IM olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM olanzapine 10 mg
Study: 3777553
Drug: Intranasal nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal nifedipine (10 mg)
Study: 3777553
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (0.3 mg X kg‐1 followed by continuous infusion of 3 micrograms X kg‐1 X min‐1)
Study: 16330196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preventive treatment)
Study: 26902281
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg/day) plus Risperidone (up to 6 mg/day)
Study: 26902281
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Risperidone (up to 6 mg/day)
Study: 19013980
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose mitomycin C (MMC) administered to 49 patients
Study: 19013980
Drug: No mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No mitomycin C administered to 51 patients
Study: 10440419
Drug: Clopidogrel 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 100 mg
Study: 10440415
Drug: Clopidogrel 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 200 mg
Study: 10440415
Drug: Clopidogrel 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 400 mg
Study: 10440415
Drug: Clopidogrel (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (400 mg, capsules and tablets)
Study: 1899364
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg rt-PA with heparin and aspirin
Study: 30477911
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) plus masking therapy and sound treatment
Study: 30477911
Drug: Masking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masking therapy and sound treatment
Study: 27730478
Drug: Action Observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action Observation Training (AOT-G)
Study: 27730478
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (C-G)
Study: 24655622
Drug: Fluoxetine 20-40mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20-40mg/day
Study: 15277317
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/d for 6 months
Study: 17519271
Drug: Oral leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral leflunomide (LEF) 30 mg/day
Study: 17519271
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) starting with 7.5 mg/week reaching 20 mg/week after 8 weeks
Study: 11293554
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel (0.1%)
Study: 11293554
Drug: Adapalene cream
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene cream (0.1%)
Study: 11293554
Drug: Erythromycin (4%)/tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (4%)/tretinoin (0.025%) solution
Study: 11293554
Drug: Erythromycin (4%)/tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (4%)/tretinoin (0.025%) gel
Study: 11293554
Drug: Erythromycin (2%)/isotretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (2%)/isotretinoin (0.05%) gel
Study: 7697479
Drug: Intranasal ragweed
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ragweed challenge (doses 10, 100, and 1000 PNU)
Study: 24252717
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin administration
Study: 22077070
Drug: Daily azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily azithromycin
Study: 17188409
Drug: Amoxicillin 2g
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 2g combined with clavulanic acid, orally daily for 5 days postoperatively
Study: 17188409
Drug: Amoxicillin 2g
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 2g combined with clavulanic acid, starting 5 days before the operation
Study: 15654549
Drug: 44 mcg
Normalized name: Tirosint 44 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 mcg subcutaneously three times weekly (tiw)
Study: 15654549
Drug: 30 mcg
Normalized name: Avonex 30 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mcg intramuscularly once weekly (qw)
Study: 11238511
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) (400-600 IU/day) and calcium (500 mg/day)
Study: 9550248
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plus marital intervention for 11 months
Study: 9550248
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management plus marital intervention
Study: 7942680
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg each morning
Study: 3227297
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg oral propranolol twice daily for 7 days
Study: 3227297
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 7 days
Study: 2232492
Drug: Sham hemodialysis
Normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham hemodialysis with indomethacin administration (Group CU-IND)
Study: 4916211
Drug: Inert tablets
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert tablets (placebo)
Study: 17557470
Drug: Zaleplon 10
Normalized name: zaleplon 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon 10 mg
Study: 9858950
Drug: Retarded morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retarded morphine (mean dosage: 49.2 +/- 28.4 mg/d)
Study: 11788564
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no further therapy)
Study: 8116539
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g native amylomaize (Hylon‐VII) three times a day for 7 days, containing 28 g type II resistant starch
Study: 3291491
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml PG E2 endocervical application
Study: 3291491
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intravaginal PG E2
Study: 17905023
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray
Study: 26076302
Drug: Ice spray
Normalized name: Tegrin-LT Lice Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice spray
Study: 23070146
Drug: Antacid suspension
Normalized name: Antacid Suspension
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid suspension 20 mL given 2 h after nilotinib 400 mg